Table 3.

Tuberculosis (TB) screening tests seroconversion rates between different biologic DMARDs and cases with seroconversion that developed active TB.

Drug	Disease	Patients	Number of Conversions	Active TB	Rate (%)	Country	Reference
Etanercept	RA	62	6	0	9.7	Italy	Cuomo et al.81
Etanercept	RA, JIA, AS	27	4	0	14.8	Italy	Cerda et al.82
Adalimumab	RA	60	11	0	18.3	Italy	Cuomo et al.81
Adalimumab	RA, JIA, AS	18	3	1	16.7	Italy	Cerda et al.82
Etanercept, Adalimumab	PsO	91	13	0	14.3	Taiwan	Cheng et al.80
Infliximab	RA	11	1	0	9.1	Italy	Cuomo et al.81
Infliximab	RA, JIA, AS	15	0	0	0	Italy	Cerda et al.82
Certolizumab	RA	19	1	0	5.3	Italy	Cuomo et al.81
Certolizumab	RA, JIA, AS	1	0	0	0	Italy	Cerda et al.82
Golimumab	RA	16	2	0	12.5	Italy	Cuomo et al.81
Golimumab	RA, JIA, AS	3	0	0	0	Italy	Cerda et al.82
Ustekinumab	PsO	109	8	0	7.3	Taiwan	Hsiao et al.79
Secukinumab	PsO	96	1	0	1	Taiwan	Wu et al.83
Tocilizumab	RA	44	7	0	15.9	Italy	Cuomo et al.81
Tocilizumab	RA, JIA, AS	13	1	0	7.7	Italy	Cerda et al.82
Abatacept	RA	37	6	0	16.2	Italy	Cuomo et al.81
Abatacept	RA, JIA, AS	8	0	0	0	Italy	Cerda et al.82
Rituximab	RA	43	0	0	0	Taiwan	Chen et al.84

AS, ankylosing spondylitis; DMARDs, disease-modifying anti-rheumatic drugs; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.